- Home
- SQFT vs PPBT Comparison
SQFT vs PPBT Comparison
Compare SQFT & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SQFT | PPBT |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | United States | Israel |
| Employees | 15 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 4.4M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | SQFT | PPBT |
|---|---|---|
| Price | $3.30 | $2.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | 25.9K | ★ 31.6K |
| Earning Date | 05-13-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.10 | $0.41 |
| 52 Week High | $23.00 | $5.18 |
Technical Indicators
Market Signals| Indicator | SQFT | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 32.32 |
| Support Level | $3.13 | $0.57 |
| Resistance Level | $3.91 | $4.39 |
| Average True Range (ATR) | 0.29 | 0.32 |
| MACD | -0.04 | -0.16 |
| Stochastic Oscillator | 39.82 | 17.53 |
Price Performance
Historical ComparisonAbout SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.